{
  "pmcid": "12275378",
  "sha256": "3c71f33de3f546987bcdf3398ec32006f558fc10de94d6823f009cccff3a7cbe",
  "timestamp_utc": "2025-11-09T22:20:33.026176+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 9.271976608187135,
    "reading_ease": 49.67926315789475,
    "word_count": 225
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Alfentanil in Hysteroscopic Surgery"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "One hundred and forty female patients, ASA grade I or II, aged 18–65 years, scheduled for hysteroscopy at Women’s Hospital, Zhejiang University, were randomised"
      },
      "Participants": {
        "score": 2,
        "evidence": "One hundred and forty female patients, ASA grade I or II, aged 18–65 years, scheduled for hysteroscopy at Women’s Hospital, Zhejiang University"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive 8 µg·kg−1, 10 µg·kg−1, 12 µg·kg−1, 14 µg·kg−1 alfentanil, or 0.15 µg·kg−1 sufentanil"
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial aimed to determine the median effective dose (ED50) and the 95% effective dose (ED95) of alfentanil"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the ED50 and ED95 of alfentanil, measured using probit analysis"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated and allocation was concealed in sealed envelopes"
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, outcome assessors, and clinicians"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "One hundred and forty female patients"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The ED50 and ED95 of alfentanil were 9.73 µg·kg−1 (95% CI 8.57 to 10.56) and 15.02 µg·kg−1 (95% CI 13.57 to 18.12), respectively"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were less frequent in the 10–12 µg·kg−1 groups compared to sufentanil"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ChiCTR2400080232"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}